Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | KCNQ3 | O43525 | 3/20 | 0.53 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19700160 | 0.88 | KCNQ3 (0.61) | HPGDKCNQ3KCNQ2MEN1KMT2A | |
| SCHEMBL4938487 | 0.83 | HPGD (0.54) | HPGDKCNQ3KCNQ2MEN1KMT2A | |
| SCHEMBL4940632 | 0.81 | HPGD (0.52) | HPGDKCNQ3KCNQ2MEN1KMT2A | |
| SCHEMBL4945563 | 0.81 | HPGD (0.52) | HPGDKCNQ3KCNQ2MEN1KMT2A | |
| SCHEMBL4941764 | 0.81 | HPGD (0.52) | HPGDKCNQ3KCNQ2MEN1KMT2A | |
| SCHEMBL4938496 | 0.81 | HPGD (0.58) | HPGDKCNQ3KCNQ2KMT2ARAB9A | |
| SCHEMBL19690300 | 0.79 | KCNQ2 (0.81) | HPGDKCNQ3KCNQ2MEN1KMT2A | |
| SCHEMBL19690597 | 0.79 | HPGD (0.52) | HPGDKCNQ3KCNQ2MEN1KMT2A | |
| SCHEMBL4939480 | 0.79 | HPGD (0.52) | HPGDKCNQ3KCNQ2MEN1KMT2A | |
| SCHEMBL21051221 | 0.79 | HPGD (0.58) | HPGDKCNQ3KCNQ2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045534-A1 | Derivatives of 1,3-diamino benzene as potassium channel modulators | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2008-02-21 | — | — | US | claimed |
| US-20080045534-A1 | Derivatives of 1,3-diamino benzene as potassium channel modulators | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045534-A1 | Derivatives of 1,3-diamino benzene as potassium channel modulators | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045534-A1 | Derivatives of 1,3-diamino benzene as potassium channel modulators | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045534-A1 | Derivatives of 1,3-diamino benzene as potassium channel modulators | KCNQ1, KCNQ2, KCNA1 | HPGD 2327/4885KCNQ3 8/4885KCNQ2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.